High-dose rifapentine with moxifloxacin for pulmonary tuberculosis

New England Journal of Medicine

Volumn 371, Issue 17, 2014, Pages 1599-1608

  Jindani, Amina ^a   Harrison, Thomas S ^a   Nunn, Andrew J ^b   Phillips, Patrick P J ^b   Churchyard, Gavin J ^c,d   Charalambous, Salome ^c   Hatherill, Mark ^e   Geldenhuys, Hennie ^e   McIlleron, Helen M ^f   Zvada, Simbarashe P ^f   Mungofa, Stanley ^g   Shah, Nasir A ^g   Zizhou, Simukai ^h   Magweta, Lloyd ^h   Shepherd, James ⁱ   Nyirenda, Sambayawo ⁱ   Van Dijk, Janneke H ^j   Clouting, Heather E ^b   Coleman, David ^a   Bateson, Anna L E ^b   McHugh, Timothy D ^b   Butcher, Philip D ^a   Mitchison, Denny A ^a   more..

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g Harare City Health Department   (Zimbabwe)

^h Medical Directorate of Mashonaland East   (Zimbabwe)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j Macha Research Trust   (Zambia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; DRUG DERIVATIVE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BOTSWANA; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MIXED INFECTION; MORTALITY; MULTICENTER STUDY; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SOUTH AFRICA; SPUTUM SMEAR; STATISTICAL SIGNIFICANCE; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; ZAMBIA; ZIMBABWE; ADOLESCENT; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; COINFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; FLUOROQUINOLONES; HIV SEROPOSITIVITY; HUMANS; ISONIAZID; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84908139920     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1314210     Document Type: Article

References (30)

1. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244- 51.
2. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946- 1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: Suppl 2: S231-79.
3. Food and Drug Administration. Priftin (rifapentine) drug approval package. October 2000(http://www.accessdata.fda.gov/drugsatfda-docs/nda/2000/21024S5-Priftin.cfm).
4. Tam CM, Chan SL, Lam CW, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis; initial report. Am J Respir Crit Care Med 1998; 157: 1726-33.
5. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIVnegative patients: a randomised clinical trial. Lancet 2002; 360: 528-34.
6. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with onceweekly rifapentine and isoniazid. Lancet 1999; 353: 1843-7.
7. Lounis N, Bentoucha A, Truffot-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001; 45: 3482-6.
8. Rosenthal IM, Williams K, Tyagi S, et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 2006; 174: 94-101.
9. Den Boon S, Bateman ED, Enarson DA, et al. Development and evaluation of a new chest radiograph reading and recording system for epidemiological surveys of tuberculosis and lung disease. Int J Tuberc Lung Dis 2005; 9: 1088-96.
10. Dawson R, Masuka P, Edwards DJ, et al. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int J Tuberc Lung Dis 2010; 14: 52-8.
11. Treatment of tuberculosis: guidelines. 4th ed. Geneva: World Health Organization, 2010.
12. Zvada SP, Van Der Walt JS, Smith PJ, et al. Effects of four different meal types on the population pharmacokinetics of single- dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother 2010; 54: 3390-4.
13. Division of AIDS. Table for grading severity of adult adverse experiences. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 1992.
14. Lienhardt C, Cook SV, Burgos M, et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA 2011; 305: 1415-23.
15. Merle CS, Sismanidis C, Sow OB, et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project. Trials 2012; 13:61.
16. REMoxTB laboratory manual. June 2011 (http://www.ucl.ac.uk/infection-immunity/research/res-ccm/ccm-files/CCM-REMox).
17. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Statistical principles for clinical trials (E9). 1998.
18. Machin D. Sample size tables for clinical studies. Chichester, United Kingdom: Wiley-Blackwell, 2009.
19. Proschan MA, Waclawiw MA. Practical guidelines for multiplicity adjustment in clinical trials. Control Clin Trials 2000; 21: 527-39.
20. Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013; 368: 1291-302.
21. Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments. Lancet 2005; 365: 1591-5.
22. Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroup and interim analyses. Lancet 2005; 365: 1657-61.
23. Nunn AJ, Phillips PPI, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 2010; 14: 241-2.
24. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4(12): e344.
25. Garton NJ, Waddell SJ, Sherratt AL, et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 2008; 5(4): e75.
26. Mitchison DA. Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins. Int J Tuberc Lung Dis 2012; 16: 1186-9.
27. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-80.
28. Zvada SP, Denti P, Geldenhuys H, et al. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine. Antimicrob Agents Chemother 2012; 56: 4471-3.
29. Bayer and TB Alliance to develop moxifloxacin for TB. Press release release of the TB Alliance, October 2005 (http://tballiance.org/newscenter/view-brief.php?id=158).
30. Tuberculosis drug maker Sanofi drops price, easing access to shortened TB infection treatment. Arlington, VA: Center for Global Health Policy. December 13, 2013 (http://sciencespeaksblog.org/2013/12/13/tb-drug-maker-drops-price -offering-hope-of-shortened-affordable -treatment).